Skin manifestations of COVID-19 in children : Part 1
© 2020 British Association of Dermatologists..
The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID-19, chilblain-like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children, for both COVID-19 and any other pre-existing conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Clinical and experimental dermatology - 46(2021), 3 vom: 06. Apr., Seite 444-450 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andina, D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.04.2021 Date Revised 28.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ced.14481 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317485016 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317485016 | ||
| 003 | DE-627 | ||
| 005 | 20231225163351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ced.14481 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317485016 | ||
| 035 | |a (NLM)33180982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andina, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Skin manifestations of COVID-19 in children |b Part 1 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2021 | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 British Association of Dermatologists. | ||
| 520 | |a The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID-19, chilblain-like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children, for both COVID-19 and any other pre-existing conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 700 | 1 | |a Belloni-Fortina, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bodemer, C |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifazi, E |e verfasserin |4 aut | |
| 700 | 1 | |a Chiriac, A |e verfasserin |4 aut | |
| 700 | 1 | |a Colmenero, I |e verfasserin |4 aut | |
| 700 | 1 | |a Diociaiuti, A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Hachem, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fertitta, L |e verfasserin |4 aut | |
| 700 | 1 | |a van Gysel, D |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Martín, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hubiche, T |e verfasserin |4 aut | |
| 700 | 1 | |a Luca, C |e verfasserin |4 aut | |
| 700 | 1 | |a Martos-Cabrera, L |e verfasserin |4 aut | |
| 700 | 1 | |a Maruani, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzotta, F |e verfasserin |4 aut | |
| 700 | 1 | |a Akkaya, A D |e verfasserin |4 aut | |
| 700 | 1 | |a Casals, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrando, J |e verfasserin |4 aut | |
| 700 | 1 | |a Grimalt, R |e verfasserin |4 aut | |
| 700 | 1 | |a Grozdev, I |e verfasserin |4 aut | |
| 700 | 1 | |a Kinsler, V |e verfasserin |4 aut | |
| 700 | 1 | |a Morren, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Munisami, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nanda, A |e verfasserin |4 aut | |
| 700 | 1 | |a Novoa, M P |e verfasserin |4 aut | |
| 700 | 1 | |a Ott, H |e verfasserin |4 aut | |
| 700 | 1 | |a Pasmans, S |e verfasserin |4 aut | |
| 700 | 1 | |a Salavastru, C |e verfasserin |4 aut | |
| 700 | 1 | |a Zawar, V |e verfasserin |4 aut | |
| 700 | 1 | |a Torrelo, A |e verfasserin |4 aut | |
| 700 | 0 | |a ESPD Group for the Skin Manifestations of COVID-19 |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental dermatology |d 1993 |g 46(2021), 3 vom: 06. Apr., Seite 444-450 |w (DE-627)NLM000126810 |x 1365-2230 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:3 |g day:06 |g month:04 |g pages:444-450 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ced.14481 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 3 |b 06 |c 04 |h 444-450 | ||